Michelle Parks's research while affiliated with Duke University and other places

What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.

It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.

If you're a ResearchGate member, you can follow this page to keep up with this author's work.

If you are this author, and you don't want us to display this page anymore, please let us know.

Publications (4)

Early Stage HER2 Positive Breast Cancers Not Achieving A pCR From Neoadjuvant Trastuzumab Or Pertuzumab Based Regimens Have An Immunosuppressive Phenotype
Article
  • Feb 2018
Background: Stromal tumor-infiltrating lymphocytes (TILs) might predict pathologic complete response (pCR) in patients with HER2-positive (HER2+) breast cancer treated with trastuzumab (H). Docetaxel (T), carboplatin (C), H, and pertuzumab (P) have immune-modulating effects. Pre- and post-treatment immune biomarkers in cancers treated with neoadju...
Abstract P4-14-16: T-cell clonality increases after neoadjuvant treatment with trastuzumab and pertuzumab
Article
  • Feb 2016
Background: Baseline TIL density and T-cell clonality predict pathological complete response (pCR) to neoadjuvant (NA) trastuzumab (TRAS). Preclinical data suggests that a major mechanism of TRAS is enhancement of antibody-dependent cytoxicity (ADCC) and T-cell mediated tumor kill and that the combination of TRAS with pertuzumab (PERT) may enhance...
Abstract S4-03: Exome sequencing reveals clinically actionable mutations in the pathogenesis and metastasis of triple negative breast cancer
Article
  • Mar 2014
Triple negative breast cancer (TNBC) represents a particularly aggressive and difficult to treat form of breast cancer. No specific genetic alterations have been described as characteristic of the disease, with the exception of association with BRCA1/2, EGFR, and KRAS mutations. In this study, we sought to define clinically actionable mutations in...

Citations

... Nevertheless, high Treg TIL quantities without CD8+ T cells were not associated with better survival in ER-positive breast cancer patients [63]. Based on the studies to date, further research is needed to clarify the role of Treg cells in tumoral immune response and their interaction with other cell populations present in the tumor [64]. Thus, future studies on their prognostic role in patient samples are necessary to finally determine the clinical importance of Treg cell assessment. ...
Reference: Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer
... In addition, there are few systematic studies of recurrent and/or metastatic disease, though some studies are now being conducted. 48,49 To further understand tumor evolution and therapeutic resistance in breast cancer, it will be imperative to catalogue the mutations present in those tumors that are metastatic at diagnosis or that recur after primary treatment. ...
Reference: Precision Medicine in Breast Cancer: Genes, Genomes, and the Future of Genomically Driven Treatments